UNICREDIT BANK/CALL/EVOTEC/22/1/19.03.25 Share Price

Warrant

DE000HD3ZZ19

Real-time BOERSE MUENCHEN 12:47:01 14/06/2024 BST
0.026 EUR +2,500.00% Intraday chart for UNICREDIT BANK/CALL/EVOTEC/22/1/19.03.25
Current month-27.78%
1 month-87.62%
Date Price Change
14/06/24 0.026 +2,500.00%
13/06/24 0.001 -96.15%
12/06/24 0.026 -10.34%
11/06/24 0.029 +20.83%
10/06/24 0.024 +4.35%

Real-time BOERSE MUENCHEN

Last update June 14, 2024 at 12:47 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying EVOTEC SE
IssuerLogo Issuer UniCredit UniCredit
WKN HD3ZZ1
ISINDE000HD3ZZ19
Date issued 21/03/2024
Strike 22
Maturity 19/03/2025 (275 Days)
Parity 1 : 1
Emission price 1.03
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.98
Lowest since issue 0.001

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.4 EUR
Average target price
20.79 EUR
Spread / Average Target
+147.50%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW